Literature DB >> 3021035

Treatment of murine histoplasmosis with UK 49,858 (fluconazole).

J R Graybill, E Palou, J Ahrens.   

Abstract

Fluconazole was compared with ketoconazole and with amphotericin B in treatment of pulmonary histoplasmosis in immunologically intact mice and in congenitally athymic nude mice. Both fluconazole and amphotericin B increased survival and reduced fungal burden in normal mice. All 3 drugs equally prolonged survival of nude mice challenged with Histoplasma capsulatum, and all effectively reduced the fungal burden. Fluconazole may be a useful antifungal drug in treatment of murine histoplasmosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3021035     DOI: 10.1164/arrd.1986.134.4.768

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  14 in total

1.  Diagnosis of Paracoccidioidomycosis by detection of antigen and antibody in bronchoalveolar lavage fluids.

Authors:  Silvia Helena Marques-da-Silva; Arnaldo Lopes Colombo; Maria Heloisa Souza Lima Blotta; Flávio Queiroz-Telles; Alípio Barbosa Balthazar; José Daniel Lopes; Zoilo Pires de Camargo
Journal:  Clin Vaccine Immunol       Date:  2006-10-11

2.  In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum.

Authors:  G S Kobayashi; S J Travis; M G Rinaldi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

Review 3.  Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis.

Authors:  K N Sorensen; K V Clemons; D A Stevens
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

4.  Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice.

Authors:  P Connolly; L J Wheat; C Schnizlein-Bick; M Durkin; S Kohler; M Smedema; J Goldberg; E Brizendine; D Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 5.  Key issues concerning fungistatic versus fungicidal drugs.

Authors:  J R Graybill; D S Burgess; T C Hardin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

Review 6.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

7.  Therapeutic effect of the triazole Bay R 3783 in mouse models of coccidioidomycosis, blastomycosis, and histoplasmosis.

Authors:  D Pappagianis; B L Zimmer; G Theodoropoulos; M Plempel; R F Hector
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

8.  Efficacy of the triazole D0870 in a murine model of systemic histoplasmosis.

Authors:  K V Clemons; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

9.  Amphotericin B lipid complex therapy of experimental fungal infections in mice.

Authors:  J M Clark; R R Whitney; S J Olsen; R J George; M R Swerdel; L Kunselman; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 10.  Fluconazole. Review and situation among antifungal drugs in the treatment of opportunistic mycoses of human immuno-deficiency virus infections.

Authors:  F N Vincent-Ballereau; O N Patey; C Lafaix
Journal:  Pharm Weekbl Sci       Date:  1991-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.